El CRAI romandrà tancat del 24 de desembre de 2025 al 6 de gener de 2026. La validació de documents es reprendrà a partir del 7 de gener de 2026.
El CRAI permanecerá cerrado del 24 de diciembre de 2025 al 6 de enero de 2026. La validación de documentos se reanudará a partir del 7 de enero de 2026.
From 2025-12-24 to 2026-01-06, the CRAI remain closed and the documents will be validated from 2026-01-07.
 
Miniatura

Fitxers

662776.pdf (3.16 MB)

Tipus de document

Article

Versió

Versió acceptada

Data de publicació

2015-03-01

Tots els drets reservats

Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/178081

A DNA methylation-based definition of biologically distinct breast cancer subtypes

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1016/j.molonc.2014.10.012

Resum

In cancer, epigenetic states are deregulated and thought to be of significance in cancer development and progression. We explored DNA methylation-based signatures in association with breast cancer subtypes to assess their impact on clinical presentation and patient prognosis. DNA methylation was analyzed using Infinium 450K arrays in 40 tumors and 17 normal breast samples, together with DNA copy number changes and subtype-specific markers by tissue microarrays. The identified methylation signatures were validated against a cohort of 212 tumors annotated for breast cancer subtypes by the PAM50 method (The Cancer Genome Atlas). Selected markers were pyrosequenced in an independent validation cohort of 310 tumors and analyzed with respect to survival, clinical stage and grade. The results demonstrate that DNA methylation patterns linked to the luminal-B subtype are characterized by CpG island promoter methylation events. In contrast, a large fraction of basal-like tumors are characterized by hypomethylation events occurring within the gene body. Based on these hallmark signatures, we defined two DNA methylation-based subtypes, Epi-LumB and Epi-Basal, and show that they are associated with unfavorable clinical parameters and reduced survival. Our data show that distinct mechanisms leading to changes in CpG methylation states are operative in different breast cancer subtypes. Importantly, we show that a few selected proxy markers can be used to detect the distinct DNA methylation-based subtypes thereby providing valuable information on disease prognosis.

Matèries

Càncer de mama, Genètica, ADN, Metilació

Matèries (anglès)

Breast cancer, Genetics, DNA, Methylation

Citació

Col·leccions

Articles publicats en revistes (Ciències Fisiològiques)
Articles publicats en revistes (Institut de Recerca Biomèdica (IRB Barcelona))

Citació

STEFANSSON, Olafur a., MORAN, Sebastian, GÓMEZ, Antonio, SAYOLS, Sergi, ARRIBAS, Carles, SANDOVAL, Juan, HILMARSDOTTIR, Holmfridur, OLAFSDOTTIR, Elinborg, TRYGGVADOTTIR, Laufey, JONASSON, Jon g., EYFJORD, Jorunn e., ESTELLER, Manel. A DNA methylation-based definition of biologically distinct breast cancer subtypes. _Molecular Oncology_. 2015. Vol. 9, núm. 3, pàgs. 555-568. [consulta: 7 de gener de 2026]. ISSN: 1574-7891. [Disponible a: https://hdl.handle.net/2445/178081]

Exportar metadades

JSON - METS

Compartir registre